UCLA AIDS Prevention and Treatment Clinical Trials Unit

加州大学洛杉矶分校艾滋病预防和治疗临床试验中心(UCLA-APT-CTU)是一个多学科的 研究单位，由洛杉矶大都会的一个核心行政单位和四个临床研究地点组成 安吉。调查团队在设计、实施、 并进行临床试验，评估治疗和预防策略。在…的领导下 朱迪思·柯里尔医学博士和包括Thomas Coates博士、Ronald Mitsuyasu在内的高级调查团队， 医学博士、医学博士Eric Daar、医学博士Cathy Reback、博士博士Steve Shoptaw和医学博士Stephen Brown，该单位将 参与设计和开展涉及以下四个优先研究领域的研究； 预防艾滋病毒感染、转化研究/药物开发、优化临床 与艾滋病临床试验小组合作进行管理和疫苗研发 艾滋病毒预防试验网络(HTPN)和疫苗试验网络(VTN)。CTU有一个 加州大学洛杉矶分校艾滋病临床研究和教育中心的行政核心和临床研究站点 (CARE中心)和其他临床研究站点(CRS)在港湾加州大学洛杉矶分校医学中心和朋友 研究机构/综合药物滥用计划(ISAP)加州大学洛杉矶分校和艾滋病研究联盟。这个 我们单位的具体目标是： 1.评估可能更有效的艾滋病毒新疗法。 2.评估在不同人群中最佳使用抗逆转录病毒疗法的策略。 3.评估优化艾滋病毒感染及相关并存管理的战略。 4.研究用于治疗和预防艾滋病毒感染的艾滋病毒疫苗。 5.评价预防高危兴奋剂和注射吸毒者感染艾滋病毒的新战略。 6.评估使用抗逆转录病毒药物预防艾滋病毒感染的战略。 7.评估对急性感染者的早期干预对长期结果的作用 传输率。 8.指导新的少数民族研究人员进行跨学科的艾滋病毒/艾滋病研究。 9.通过参与ACTG、HPTN和VTN的领导，作出重大贡献 小组领导、科学委员会和礼宾团队。 10.鼓励社区参与，鼓励妇女和种族/族裔少数群体参与 UCLA-APT-CTU的ACTG、HPTN和VTN临床试验。

The UCLA AIDS Prevention and Treatment Clinical Trials Unit (UCLA-APT-CTU) is a multidisciplinary research unit composed of a core administrative unit and four clinical research sites in metropolitan Los Angeles. The investigative team has over 15 years of leadership experience in the design, implementation, and conduct of clinical trials evaluating both therapeutic and prevention strategies. Under the leadership of Judith Currier MD, MSc and a senior investigator team including Thomas Coates, PhD, Ronald Mitsuyasu, MD, Eric Daar, MD, Cathy Reback, Ph D, Steve Shoptaw, PhD and Stephen Brown MD, the unit will participate in the design and conduct of studies addressing the following four priority research areas; Prevention of HIV Infection, Translational Research/Drug Development, Optimization of Clinical Management, and Vaccine Research and Development in collaboration with the AIDS Clinical Trials Group (ACTG), the HIV Prevention Trials Network (HTPN) and the Vaccine Trials Network (VTN). The CTU has an administrative core and clinical research site at the UCLA Center for Clinical AIDS Research and Education (CARE Center) and additional Clinical Research Sites (CRS) at Harbor UCLA Medical Center and Friends Research Institute/Integrated Substance Abuse Program (ISAP) UCLA and AIDS Research Alliance. The specific aims of our unit are to: 1. Evaluate new and potentially more effective HIV treatments. 2. Evaluate strategies for optimal use of antiretroviral therapies (ARV) in diverse populations. 3. Evaluate strategies to optimize the management of HIV infection and related co-morbidities. 4. Investigate HIV vaccines for therapy and for prevention of HIV infection. 5. Evaluate novel strategies for prevention of HIV infection in high-risk stimulant and injection drug users. 6. Evaluate strategies using ARV to prevent HIV acquisition. 7. Assess the role of early interventions in acutely infected individuals on long-term outcomes and transmission rates. 8. Mentor new minority investigators in cross-disciplinary HIV/AIDS research. 9. Make significant contributions to the leadership of the ACTG, HPTN and VTN through participation in the group leadership, scientific committees and protocol teams. 10. Stimulate community involvement and encourage participation of women and racial/ethnic minorities in ACTG, HPTN and VTN clinical trials at the UCLA-APT-CTU.